Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
OMAHA, NE—Berkshire Hathaway Inc. (NYSE:BRK.A), led by Warren E. Buffett, has reported the sale of DaVita Inc . (NYSE:DVA) shares totaling approximately $27.8 million, according to a recent SEC filing. The transactions occurred over several days, with prices ranging from $137.28 to $140.18 per share for the healthcare provider, which currently maintains a market capitalization of $10.5 billion and trades at a P/E ratio of 13.5.
On May 22, Berkshire Hathaway (NYSE:BRKa) sold 31,404 shares at a weighted average price of $138.94 and an additional 1,256 shares at $139.88. The following day, the company sold 27,172 shares at $137.28 and 36,094 shares at $138.19, along with a smaller transaction of 800 shares at $138.60.
Further sales occurred on May 27, with 19,330 shares sold at $138.59 and 71,966 shares at $139.56. The final transaction involved 11,978 shares at a price of $140.18. Following these transactions, Berkshire Hathaway’s holdings in DaVita stand at 33,796,541 shares.
Berkshire Hathaway, known for its significant investments across various sectors, continues to manage its portfolio actively, with these transactions reflecting strategic decisions regarding its stake in DaVita.
In other recent news, DaVita Inc. reported its first-quarter earnings for 2025, surpassing analysts’ expectations with an adjusted EPS of $2.00, compared to a forecast of $1.96. The company also reported revenue of $3.22 billion, slightly above the projected $3.20 billion. Despite these positive results, TD Cowen maintained a Hold rating on DaVita shares but reduced the price target from $165 to $157, citing increased flu cases and weather-related impacts as contributing factors to the company’s underperformance. DaVita has also announced an upsized private offering of senior notes due 2033, increasing the aggregate principal amount from $750 million to $1 billion. The proceeds from these notes will primarily be used to repay existing revolving credit facility borrowings. Additionally, DaVita experienced operational challenges, including a cyber incident and a severe flu season, which led to a revision of its full-year volume expectations downward by 50 basis points. Despite these setbacks, the company has reaffirmed its full-year guidance for EBIT, EPS, and free cash flow. The company’s recent earnings report and subsequent price target revision reflect the impact of external factors on its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.